Cointime

Seagen

company

About

Seagen is dedicated to improving patient outcomes with advanced antibody-drug conjugate technology.

Highlights

Stock Symbol
nasdaq:SGEN
Total Funding Amount
$1.78B
Funding Rounds
7
Investors
4
Investments
1
Exits
2

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$1B
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 1998
Number Of Employee
1001 - 5000
Operating Status
Active
Stock Symbol
nasdaq:SGEN
Legal Name
Seattle Genetics, Inc.
Also Known As
Seattle Genetics

Seattle Genetics is a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in the pivotal trial for patients with relapsed or refractory Hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
7
$1.78B
Seagen has raised a total of $1.78B in funding over 2 rounds. Their latest funding was raised on Sep 14, 2020 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 14, 2020 Post-IPO Equity $1B 1 Merck — Detail
Jul 26, 2019 Post-IPO Equity $575M — — — Detail
Jan 17, 2014 Post-IPO Equity $9M 1 — — Detail
Feb 2, 2011 Post-IPO Equity $155M — — — Detail
Jan 1, 2009 Post-IPO Equity — 1 — — Detail
Show More

Investments

Number of Investments
Number of Lead Investments
1
0
Seagen has made 1 investments. Their most recent investment was on Jun 11, 2015, when Cogent Biosciences raised $65M.
Date Company Name
Round Money Raised Industry Lead Investor
Jun 11, 2015 Cogent Biosciences
Series B $65M Biotechnology —

Investors

Number of Lead Investors
Number of Investors
1
4
Seagen is funded by 4 investors. Merck and Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
Merck Yes Post-IPO Equity
Takeda — Post-IPO Equity
New Enterprise Associates — Post-IPO Equity
Sofinnova Investments — Series Unknown

Employee Profiles

Number of Employee Profiles
26
Seagen has 26 current employee profiles, including Executive Mark Cooley
Mark Cooley
Executive
Jean Liu
Executive
Lee Heeson
Executive
Wendel Doubleday
Executive
Show More

Exits

Seagen has had 2 exits. Seagen most notable exits include Cogent Biosciences ,   Pieris Pharmaceuticals

Date Company Name Exit Type Industry
Mar 29, 2018 Cogent Biosciences IPO Biotechnology Detail
Jan 9, 2015 Pieris Pharmaceuticals IPO Biopharma Detail

Acquisition

Seagen has acquired 1 organizations. Their most recent acquisition was Cascadian Therapeutics on Jan 31, 2018. They acquired Cascadian Therapeutics for $614M.

Date Company Name
Industry Acquisition Type Price
Jan 31, 2018 Cascadian Therapeutics
Biotechnology acquisition $ 614M Detail
Cointime
เนื้อหา
บริษัท